DR. BRUCE E REIDENBERG, M.D.
Medical Practice at Stoneycrest Rd, Rye, NY
License number
New York 169073
Category
Medical Practice
Type
Pediatrics
License number
New York 61086
Category
Medical Practice
Type
Pediatrics
Address
Address
1 Stoneycrest Rd, Rye, NY 10580
Phone
(914) 925-2597
Personal information
See more information about BRUCE E REIDENBERG at radaris.comName
Address
Phone
1 Stoneycrest Rd, Rye, NY 10580
Professional information
Transdermal Dosage Form Comprising An Active Agent And A Salt And Free-Base Form Of An Adverse Agent
US Patent:
2004012, Jul 1, 2004
Filed:
Aug 20, 2003
Appl. No.:
10/645654
Inventors:
Ihor Shevchuk - Yonkers NY, US
Bruce Reidenberg - Rye NY, US
Bruce Reidenberg - Rye NY, US
International Classification:
A61K049/00, A61K009/70
US Classification:
424/010100, 424/449000
Abstract:
This invention relates to a tamper-resistant transdermal dosage form comprising an active agent, such as an opioid, or a pharmaceutically acceptable salt thereof, a free base of an adverse agent, such as an opioid antagonist, and a pharmaceutically acceptable salt of an adverse agent, such as an opioid antagonist. The transdermal dosage form allows an effective amount of the active agent, or a pharmaceutically acceptable salt thereof, to be transdermally administered to an animal. The invention further relates to methods for treating or preventing pain in an animal comprising contacting the skin of an animal in need thereof with the transdermal dosage form of the invention for an amount of time sufficient to treat or prevent pain.
Dr. Bruce E Reidenberg, Rye NY - MD (Doctor of Medicine)
Specialties:
Pediatrics
Address:
1 Stoneycrest Rd, Rye 10580
(914) 925-2597 (Phone)
(914) 925-2597 (Phone)
Certifications:
Pediatrics, 2011
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Weill Cornell Medical College
Graduated: 1985
New York Presbyterian Hospital-New York Weill Cornell Center
Mount Sinai Hospital
Weill Cornell Medical College
Graduated: 1985
New York Presbyterian Hospital-New York Weill Cornell Center
Mount Sinai Hospital
Abuse Resistant Opioid Transdermal Delivery Device Containing Opioid Antagonist Microspheres
US Patent:
2008023, Sep 25, 2008
Filed:
Feb 15, 2005
Appl. No.:
10/584816
Inventors:
Bruce Reidenberg - Rye NY, US
Ihor Shevchuk - Yonkers NY, US
Lino Tavares - Kinnelon NJ, US
Richard Maskiewicz - Ridgefield CT, US
Kevin Long - Oak Ridge NJ, US
Mohammed Shameem - Nanuet NY, US
Ihor Shevchuk - Yonkers NY, US
Lino Tavares - Kinnelon NJ, US
Richard Maskiewicz - Ridgefield CT, US
Kevin Long - Oak Ridge NJ, US
Mohammed Shameem - Nanuet NY, US
Assignee:
EURO-CELTIQUE S.A. - LUXEMBOURG
International Classification:
A61K 9/70, A61K 31/485
US Classification:
424449, 514282
Abstract:
The present invention provides abuse-resistant transdermal delivery devices containing an opioid agonist intended for analgesic purposes in pain patients.
Treatment Of Dependence Withdrawal
US Patent:
8637073, Jan 28, 2014
Filed:
Jul 26, 2004
Appl. No.:
10/566121
Inventors:
Bruce E. Reidenberg - Rye NY, US
Daniel A. Spyker - Burlingame CA, US
Daniel A. Spyker - Burlingame CA, US
Assignee:
Purdue Pharma L.P. - Stamford CT
International Classification:
A61F 13/02
US Classification:
424448, 424449
Abstract:
Dosage regimens of buprenorphine to treat withdrawal or abstinence syndrome in a drug dependent or opioid tolerant patient who is pregnant are described. The method includes treating withdrawal or abstinence syndrome of the patient by transdermal administration of an amount of buprenorphine effective to reduce withdrawal symptoms. For example, a first buprenorphine-containing transdermal dosage form can be administered for a first dosing period that is no more than about 5 days; a second buprenorphine-containing transdermal dosage form for a second dosing period that is no more than about 5 days, the second dosage form comprising the same or a greater dosage of buprenorphine than the first dosage form; and a third buprenorphine-containing transdermal dosage form for a third dosing period that is at least 2 days, the third dosage form comprising the same or a greater dosage of buprenorphine than the second dosage form.
Preoperative Treatment Of Post Operative Pain
US Patent:
2011000, Jan 6, 2011
Filed:
Sep 13, 2010
Appl. No.:
12/880952
Inventors:
Bruce E. REIDENBERG - Rye NY, US
Daniel A. Spyker - Burlingame CA, US
Daniel A. Spyker - Burlingame CA, US
Assignee:
PURDUE PHARMA L.P. - Stamford CT
International Classification:
A61K 31/485, A61P 25/04, A61K 9/70
US Classification:
424443, 514279
Abstract:
A method of treating postoperative pain in a patient undergoing a surgery is described. The method is based on preoperative administration of a buprenorphine-containing transdermal dosage form. The dosage form can be administered to the patient, for example, 1-4 days prior to surgery. Alternative embodiments of the invention include subsequent transdermal dosage forms to treat the postoperative pain.
Acyl Opioid Antagonists
US Patent:
2004003, Feb 19, 2004
Filed:
Feb 14, 2003
Appl. No.:
10/366394
Inventors:
Ihor Shevchuk - Yonkers NY, US
James Cassidy - Cortlandt Manor NY, US
Bruce Reidenberg - Rye NY, US
Dale Sharp - Peekskill NY, US
Robert Kupper - East Greenwich RI, US
James Cassidy - Cortlandt Manor NY, US
Bruce Reidenberg - Rye NY, US
Dale Sharp - Peekskill NY, US
Robert Kupper - East Greenwich RI, US
International Classification:
A61K009/70
US Classification:
424/449000
Abstract:
This invention relates to a tamper-resistant transdermal-delivery device comprising an opioid, or a pharmaceutically acceptable salt thereof, and an acyl opioid antagonist, or a pharmaceutically acceptable salt thereof. The transdermal-delivery device allows an analgesically effective amount of the opioid, or a pharmaceutically acceptable salt thereof, to be transdermally administered to a patient. The invention further relates to methods for treating or preventing pain in a patient comprising contacting the skin of a patient in need thereof with the transdermal-delivery device of the invention for an amount of time sufficient to treat or prevent pain. The invention further relates to acyl opioid antagonists.
Abuse Resistant Opioid Containing Transdermal Systems
US Patent:
2004024, Dec 2, 2004
Filed:
Nov 20, 2003
Appl. No.:
10/476601
Inventors:
Lino Tavares - Kinnelon NJ, US
Bruce Reidenberg - Rye NY, US
Richard Sackler - Greenwich CT, US
Curtis Wright - Norwalk CT, US
Mark Alfonso - Easton CT, US
Benjamin Oshlack - New York NY, US
James Cassidy - Cortlandt NY, US
Anthony Carpanzano - Sherman CT, US
Rampurna Gullapalli - Elmsford NY, US
Ihor Shevchuk - Yonkers NY, US
Bruce Reidenberg - Rye NY, US
Richard Sackler - Greenwich CT, US
Curtis Wright - Norwalk CT, US
Mark Alfonso - Easton CT, US
Benjamin Oshlack - New York NY, US
James Cassidy - Cortlandt NY, US
Anthony Carpanzano - Sherman CT, US
Rampurna Gullapalli - Elmsford NY, US
Ihor Shevchuk - Yonkers NY, US
International Classification:
A61K009/70
US Classification:
424/449000
Abstract:
The present invention relates to transdermal dosage form (FIG. -) comprising at least one activating agent and at least one inactivating agent. The dosage form (FIG. -) releases the inactivating agent upon disruption of the dosage form (FIG. -) thereby preventing or hindering misuse of the active agent contained in the dosage form (FIG. -).
N-But-E-Enyl Norbuprenorphine And Methods Of Use
US Patent:
2005019, Sep 1, 2005
Filed:
May 2, 2005
Appl. No.:
11/120524
Inventors:
Bruce Reidenberg - Rye NY, US
Vinayak Srinivasan - Monsey NY, US
Vinayak Srinivasan - Monsey NY, US
International Classification:
A61K031/485
US Classification:
514279000
Abstract:
The present invention provides compound having the structure:
and pharmaceutically acceptable salts or derivatives thereof, as well as compositions including such compounds. The invention also provides methods of (1) preventing pain, (2) treating pain, (3) inducing sedation, (4) treating opiate addiction, (5) treating opiate withdrawal (abstinence syndrome) and/or (6) treating cough in a patient in need thereof by administering a compound or composition of the invention.
Tamper Resistant Transdermal Dosage Form
US Patent:
2005000, Jan 6, 2005
Filed:
Apr 30, 2004
Appl. No.:
10/835535
Inventors:
Stephen Howard - Danbury CT, US
Bruce Reidenberg - Rye NY, US
Bruce Reidenberg - Rye NY, US
International Classification:
A61K009/70
US Classification:
424449000
Abstract:
The invention comprises a transdermal dosage form comprising an active agent component comprising an active agent and an adverse agent component comprising an adverse agent, wherein the active agent component defines at least one channel extending substantially there through.
Tamper Resistant Transdermal Dosage Form
US Patent:
2006019, Sep 7, 2006
Filed:
Nov 18, 2005
Appl. No.:
11/281884
Inventors:
Stephen Howard - Danbury CT, US
Bruce Reidenberg - Rye NY, US
Bruce Reidenberg - Rye NY, US
Assignee:
Purdue Pharma L.P. - Stamford CT
International Classification:
A61K 9/70
US Classification:
424449000
Abstract:
The invention comprises a transdermal dosage form comprising an active agent component comprising an active agent and an adverse agent component comprising an adverse agent, wherein the active agent component defines at least one channel extending substantially there through.